Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Wiggins BS, Dixon DL, Neyens RR, Page RL 2nd, Gluckman TJ. Select drug-drug interactions with direct oral anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341-1350.
2. Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs. 2019;79(15):1625-1634.
3. TRC Healthcare. Clinical Resource: Cytochrome P450 (CYP) Drug Interactions. Pharmacist's Letter/Prescriber's Letter. June 2020.
4. TRC Healthcare. Clinical Resource: P-glycoprotein Drug Interactions.Pharmacist's Letter/Prescriber's Letter. June 2020.
5. Tirona RG, Kim RB. Introduction to clinical pharmacology. In: Robertson D, Williams GH (eds). Clinical and Translational Science: Principles of Human Research. 2nd ed. London: Elsevier; 2017.
6. Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010;70(5):645-655.
7. U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Last accessed October 6, 2023.
8. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev. 2003;55(1):53-81.
9. Akamine Y, Yasui-Furukori N, Uno T. Drug-drug interactions of P-gp substrates unrelated to CYP metabolism. Curr Drug Metab. 2019;20(2):124-129.
10. Anticoagulation Centers of Excellence. Direct Oral Anticoagulant (DOAC) Drug-Drug Interaction Guidance. Available at https://acforum-excellence.org/Resource-Center/resource_files/-2023-02-08-064454.pdf. Last accessed October 6, 2023.
11. TRC Healthcare. Know Which DOAC Interactions Require a Med Change. Pharmacist's Letter/Prescriber's Letter. May 2023.
12. Abraham S, Nohria A, Neilan TG, et al. Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80(20):1912-1924.
13. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
14. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.
15. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(5):629-658.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.